KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) EBT (2016 - 2025)

Historic EBT for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to $700.0 million.

  • Boston Scientific's EBT rose 1965.81% to $700.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.4 billion, marking a year-over-year increase of 4833.48%. This contributed to the annual value of $3.4 billion for FY2025, which is 4833.48% up from last year.
  • According to the latest figures from Q4 2025, Boston Scientific's EBT is $700.0 million, which was up 1965.81% from $939.0 million recorded in Q3 2025.
  • In the past 5 years, Boston Scientific's EBT ranged from a high of $941.0 million in Q2 2025 and a low of $119.0 million during Q4 2021
  • In the last 5 years, Boston Scientific's EBT had a median value of $463.5 million in 2021 and averaged $493.5 million.
  • The largest annual percentage gain for Boston Scientific's EBT in the last 5 years was 137727.27% (2021), contrasted with its biggest fall of 6123.78% (2021).
  • Over the past 5 years, Boston Scientific's EBT (Quarter) stood at $119.0 million in 2021, then skyrocketed by 232.77% to $396.0 million in 2022, then rose by 27.53% to $505.0 million in 2023, then increased by 15.84% to $585.0 million in 2024, then rose by 19.66% to $700.0 million in 2025.
  • Its last three reported values are $700.0 million in Q4 2025, $939.0 million for Q3 2025, and $941.0 million during Q2 2025.